Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma
Phase II Study in Patients With Metastatic Melanoma Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of gp100 Reactive Peripheral Blood Lymphocytes (PBL) and High or Low Dose Aldesleukin
Status: Enrolling
Updated:  9/28/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma
Phase II Study in Patients With Metastatic Melanoma Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of gp100 Reactive Peripheral Blood Lymphocytes (PBL) and High or Low Dose Aldesleukin
Status: Enrolling
Updated: 9/28/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Mechanisms Regulating Wound Vascularization
Mechanisms Regulating Wound Vascularization
Status: Enrolling
Updated:  9/28/2015
OSU East Wound Care Center
mi
from
Columbus, OH
Mechanisms Regulating Wound Vascularization
Mechanisms Regulating Wound Vascularization
Status: Enrolling
Updated: 9/28/2015
OSU East Wound Care Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Mechanisms Regulating Wound Vascularization
Mechanisms Regulating Wound Vascularization
Status: Enrolling
Updated:  9/28/2015
OSU Comprehensive Wound Care Center Morehouse
mi
from
Columbus, OH
Mechanisms Regulating Wound Vascularization
Mechanisms Regulating Wound Vascularization
Status: Enrolling
Updated: 9/28/2015
OSU Comprehensive Wound Care Center Morehouse
mi
from
Columbus, OH
Click here to add this to my saved trials
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy
Status: Enrolling
Updated:  9/28/2015
Tower Cancer Research Foundation
mi
from
Beverly Hills, CA
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy
Status: Enrolling
Updated: 9/28/2015
Tower Cancer Research Foundation
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy
Status: Enrolling
Updated:  9/28/2015
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy
Status: Enrolling
Updated: 9/28/2015
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy
Status: Enrolling
Updated:  9/28/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy
Status: Enrolling
Updated: 9/28/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy
Status: Enrolling
Updated:  9/28/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy
Status: Enrolling
Updated: 9/28/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy
Status: Enrolling
Updated:  9/28/2015
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy
Status: Enrolling
Updated: 9/28/2015
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
Click here to add this to my saved trials
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy
Status: Enrolling
Updated:  9/28/2015
City of Hope South Pasadena
mi
from
South Pasadena, CA
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy
Status: Enrolling
Updated: 9/28/2015
City of Hope South Pasadena
mi
from
South Pasadena, CA
Click here to add this to my saved trials
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy
Status: Enrolling
Updated:  9/28/2015
University of Pittsburgh Cancer Institute (UPCI)
mi
from
Pittsburgh, PA
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy
Status: Enrolling
Updated: 9/28/2015
University of Pittsburgh Cancer Institute (UPCI)
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer
The Role of TAB3 Protein in Tumorigenesis
Status: Enrolling
Updated:  9/28/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer
The Role of TAB3 Protein in Tumorigenesis
Status: Enrolling
Updated: 9/28/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Digital Mammography for the Detection and Preoperative Staging of Breast Cancer
Dual Energy Contrast Enhanced Digital Mammography for the Detection and Preoperative Staging of Breast Cancer
Status: Enrolling
Updated:  9/28/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Digital Mammography for the Detection and Preoperative Staging of Breast Cancer
Dual Energy Contrast Enhanced Digital Mammography for the Detection and Preoperative Staging of Breast Cancer
Status: Enrolling
Updated: 9/28/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
Addition of the Gamma-Secretase Inhibitor RO4929097 to Erlotinib in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  9/28/2015
M D Anderson Cancer Center
mi
from
Houston, TX
RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
Addition of the Gamma-Secretase Inhibitor RO4929097 to Erlotinib in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 9/28/2015
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Beebe Medical Center
mi
from
Lewes, DE
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Beebe Medical Center
mi
from
Lewes, DE
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Christiana Care Health System - Christiana Hospital
mi
from
Newark, DE
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Christiana Care Health System - Christiana Hospital
mi
from
Newark, DE
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
MedStar Washington Hospital Center
mi
from
Washington,
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
MedStar Washington Hospital Center
mi
from
Washington,
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Kapiolani Medical Center for Women and Children
mi
from
Honolulu, HI
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Kapiolani Medical Center for Women and Children
mi
from
Honolulu, HI
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Queen's Medical Center
mi
from
Honolulu, HI
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Queen's Medical Center
mi
from
Honolulu, HI
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Oncare Hawaii Inc-Kuakini
mi
from
Honolulu, HI
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Oncare Hawaii Inc-Kuakini
mi
from
Honolulu, HI
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Straub Clinic And Hospital
mi
from
Honolulu, HI
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Straub Clinic And Hospital
mi
from
Honolulu, HI
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Castle Medical Center
mi
from
Kailua, HI
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Castle Medical Center
mi
from
Kailua, HI
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Wilcox Memorial Hospital and Kauai Medical Clinic
mi
from
Lihue, HI
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Wilcox Memorial Hospital and Kauai Medical Clinic
mi
from
Lihue, HI
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Illinois CancerCare-Bloomington
mi
from
Bloomington, IL
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Illinois CancerCare-Bloomington
mi
from
Bloomington, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Illinois CancerCare - Canton
mi
from
Canton, IL
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Illinois CancerCare - Canton
mi
from
Canton, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Graham Hospital Association
mi
from
Canton, IL
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Graham Hospital Association
mi
from
Canton, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Illinois CancerCare - Carthage
mi
from
Carthage, IL
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Illinois CancerCare - Carthage
mi
from
Carthage, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Memorial Hospital
mi
from
Carthage, IL
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Memorial Hospital
mi
from
Carthage, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Eureka Hospital
mi
from
Eureka, IL
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Eureka Hospital
mi
from
Eureka, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Illinois CancerCare - Eureka
mi
from
Eureka, IL
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Illinois CancerCare - Eureka
mi
from
Eureka, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Illinois CancerCare - Havana
mi
from
Havana, IL
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Illinois CancerCare - Havana
mi
from
Havana, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Mason District Hospital
mi
from
Havana, IL
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Mason District Hospital
mi
from
Havana, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Illinois CancerCare - Kewanee Clinic
mi
from
Kewanee, IL
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Illinois CancerCare - Kewanee Clinic
mi
from
Kewanee, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
McDonough District Hospital
mi
from
Macomb, IL
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
McDonough District Hospital
mi
from
Macomb, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Illinois CancerCare - Macomb
mi
from
Macomb, IL
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Illinois CancerCare - Macomb
mi
from
Macomb, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Illinois CancerCare - Monmouth
mi
from
Monmouth, IL
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Illinois CancerCare - Monmouth
mi
from
Monmouth, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Holy Family Medical Center
mi
from
Monmouth, IL
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Holy Family Medical Center
mi
from
Monmouth, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
BroMenn Regional Medical Center
mi
from
Normal, IL
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
BroMenn Regional Medical Center
mi
from
Normal, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Community Cancer Center
mi
from
Normal, IL
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Community Cancer Center
mi
from
Normal, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Illinois CancerCare-Ottawa Clinic
mi
from
Ottawa, IL
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Illinois CancerCare-Ottawa Clinic
mi
from
Ottawa, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Pekin Cancer Treatment Center
mi
from
Pekin, IL
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Pekin Cancer Treatment Center
mi
from
Pekin, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Illinois CancerCare - Pekin
mi
from
Pekin, IL
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Illinois CancerCare - Pekin
mi
from
Pekin, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Methodist Medical Center of Illinois
mi
from
Peoria, IL
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Methodist Medical Center of Illinois
mi
from
Peoria, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Proctor Hospital
mi
from
Peoria, IL
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Proctor Hospital
mi
from
Peoria, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Illinois CancerCare - Peru
mi
from
Peru, IL
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Illinois CancerCare - Peru
mi
from
Peru, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Perry Memorial Hospital
mi
from
Princeton, IL
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Perry Memorial Hospital
mi
from
Princeton, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Illinois CancerCare - Princeton
mi
from
Princeton, IL
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Illinois CancerCare - Princeton
mi
from
Princeton, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Illinois CancerCare - Spring Valley
mi
from
Spring Valley, IL
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Illinois CancerCare - Spring Valley
mi
from
Spring Valley, IL
Click here to add this to my saved trials
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated:  9/28/2015
Reid Hospital & Health Care Services
mi
from
Richmond, IN
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status: Enrolling
Updated: 9/28/2015
Reid Hospital & Health Care Services
mi
from
Richmond, IN
Click here to add this to my saved trials